Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010
Abstract On February 17–18, 2010, the World Health Organization (WHO) convened the 6th meeting on the “Evaluation of pandemic influenza vaccines in clinical trials” to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2010-10, Vol.28 (42), p.6811-6820 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6820 |
|---|---|
| container_issue | 42 |
| container_start_page | 6811 |
| container_title | Vaccine |
| container_volume | 28 |
| creator | Girard, Marc P Katz, Jacqueline Pervikov, Yuri Palkonyay, Laszlo Kieny, Marie-Paule |
| description | Abstract On February 17–18, 2010, the World Health Organization (WHO) convened the 6th meeting on the “Evaluation of pandemic influenza vaccines in clinical trials” to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were reviewed, including classical egg-derived and cell culture-derived inactivated vaccines, such as split virus or whole-virion vaccines, and live-attenuated vaccines (LAIV), as well as vaccines developed using new technologies. The amount of antigen needed, the effect of adjuvants and the number of doses required to induce adequate antibody responses in various populations, together with the issue of safety of the vaccines, were major topics of the meeting. The effectiveness of H1N1 vaccines and the need for standardization of vaccine potency tests were also discussed. Independent of the vaccine type and the presence or absence of an adjuvant, all A (H1N1) 2009 vaccines were well tolerated, eliciting only mild to moderate local or systemic reactions. For most vaccines tested, a single dose was sufficient to elicit a potentially protective antibody response in the majority of vaccinees >10 years of age. However, a second dose of vaccine was needed to boost immune responses in infants and toddlers 6 months to 3 years of age and, with some vaccines, in children aged 3–9 years. |
| doi_str_mv | 10.1016/j.vaccine.2010.07.034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_899130638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X10010297</els_id><sourcerecordid>3216318641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-30db6584c2ba1e94c64231e7ea336ecd327150142182491378e1fcaf525f784b3</originalsourceid><addsrcrecordid>eNqFks1u1DAUhS0EokPhEUCWWLCZDP53sgGhirZIlSpREOwsx7lpPWScwU4GdVa8A4_Am_EkOJ0pSN10Zfnq3M_33GOEnlOyoISq18vFxjrnAywYyTWiF4SLB2hGS80LJmn5EM0IU6IQlHw9QE9SWhJCJKfVY3TAiJKVZGSGfn-EdR8H3Ld4uAKshiu8Ahh8uMR9uCnBxnajHXy-ZtHahgZW3mEf2m6EsLV4P0fKJew6H7yzHR6it13CX_rYNfgUbJfB5_HSBr-9Yc3xCYSMnuOLH37YQuwyeI6p_vPzFy3xMdRxtPEaT-aeokdthsGz_XmIPh-__3R0Wpydn3w4endWOKHIUHDS1EqWwrHaUqiEU4JxChos5wpcw5mmklDBaMlERbkugbbOtpLJVpei5ofo1Y67jv33EdJgVj456PJo0I_JlFXuIoqX9yq1lFRJxnRWvryjXPZjDNmGoaLSjCkteVbJncrFPqUIrVlHv8r-DSVmitsszX7NZtqIIdrkuHPfiz19rFfQ_Ou6zTcL3u4EkPe28RBNch6Cg8ZHcINpen_vE2_uEG4z_gbXkP67MYkZYi6mPzd9OUoyhFWa_wXOzNKv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497226753</pqid></control><display><type>article</type><title>Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Girard, Marc P ; Katz, Jacqueline ; Pervikov, Yuri ; Palkonyay, Laszlo ; Kieny, Marie-Paule</creator><creatorcontrib>Girard, Marc P ; Katz, Jacqueline ; Pervikov, Yuri ; Palkonyay, Laszlo ; Kieny, Marie-Paule</creatorcontrib><description>Abstract On February 17–18, 2010, the World Health Organization (WHO) convened the 6th meeting on the “Evaluation of pandemic influenza vaccines in clinical trials” to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were reviewed, including classical egg-derived and cell culture-derived inactivated vaccines, such as split virus or whole-virion vaccines, and live-attenuated vaccines (LAIV), as well as vaccines developed using new technologies. The amount of antigen needed, the effect of adjuvants and the number of doses required to induce adequate antibody responses in various populations, together with the issue of safety of the vaccines, were major topics of the meeting. The effectiveness of H1N1 vaccines and the need for standardization of vaccine potency tests were also discussed. Independent of the vaccine type and the presence or absence of an adjuvant, all A (H1N1) 2009 vaccines were well tolerated, eliciting only mild to moderate local or systemic reactions. For most vaccines tested, a single dose was sufficient to elicit a potentially protective antibody response in the majority of vaccinees >10 years of age. However, a second dose of vaccine was needed to boost immune responses in infants and toddlers 6 months to 3 years of age and, with some vaccines, in children aged 3–9 years.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2010.07.034</identifier><identifier>PMID: 20659520</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Allergy and Immunology ; Antibodies, Viral - blood ; Cell culture ; Child ; Child, Preschool ; Clinical trials ; Congresses as Topic ; Eggs ; H1N1 influenza ; Humans ; Infant ; Influenza A Virus, H1N1 Subtype ; Influenza A Virus, H5N1 Subtype ; Influenza vaccines ; Influenza Vaccines - immunology ; Influenza Vaccines - standards ; Influenza, Human - prevention & control ; Licenses ; Manufacturers ; Meetings ; Older people ; Pandemic influenza ; Pandemics ; Pandemics - prevention & control ; Pediatrics ; Pharmaceutical industry ; Swine flu ; Vaccines ; Vaccines, Attenuated - immunology ; Vaccines, Attenuated - standards ; Vaccines, Inactivated - immunology ; Vaccines, Inactivated - standards ; Viruses ; Womens health ; World Health Organization</subject><ispartof>Vaccine, 2010-10, Vol.28 (42), p.6811-6820</ispartof><rights>World Health Organization</rights><rights>2010 World Health Organization</rights><rights>Copyright © 2010 World Health Organization. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 4, 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-30db6584c2ba1e94c64231e7ea336ecd327150142182491378e1fcaf525f784b3</citedby><cites>FETCH-LOGICAL-c460t-30db6584c2ba1e94c64231e7ea336ecd327150142182491378e1fcaf525f784b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1497226753?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20659520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Girard, Marc P</creatorcontrib><creatorcontrib>Katz, Jacqueline</creatorcontrib><creatorcontrib>Pervikov, Yuri</creatorcontrib><creatorcontrib>Palkonyay, Laszlo</creatorcontrib><creatorcontrib>Kieny, Marie-Paule</creatorcontrib><title>Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract On February 17–18, 2010, the World Health Organization (WHO) convened the 6th meeting on the “Evaluation of pandemic influenza vaccines in clinical trials” to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were reviewed, including classical egg-derived and cell culture-derived inactivated vaccines, such as split virus or whole-virion vaccines, and live-attenuated vaccines (LAIV), as well as vaccines developed using new technologies. The amount of antigen needed, the effect of adjuvants and the number of doses required to induce adequate antibody responses in various populations, together with the issue of safety of the vaccines, were major topics of the meeting. The effectiveness of H1N1 vaccines and the need for standardization of vaccine potency tests were also discussed. Independent of the vaccine type and the presence or absence of an adjuvant, all A (H1N1) 2009 vaccines were well tolerated, eliciting only mild to moderate local or systemic reactions. For most vaccines tested, a single dose was sufficient to elicit a potentially protective antibody response in the majority of vaccinees >10 years of age. However, a second dose of vaccine was needed to boost immune responses in infants and toddlers 6 months to 3 years of age and, with some vaccines, in children aged 3–9 years.</description><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Cell culture</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical trials</subject><subject>Congresses as Topic</subject><subject>Eggs</subject><subject>H1N1 influenza</subject><subject>Humans</subject><subject>Infant</subject><subject>Influenza A Virus, H1N1 Subtype</subject><subject>Influenza A Virus, H5N1 Subtype</subject><subject>Influenza vaccines</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza Vaccines - standards</subject><subject>Influenza, Human - prevention & control</subject><subject>Licenses</subject><subject>Manufacturers</subject><subject>Meetings</subject><subject>Older people</subject><subject>Pandemic influenza</subject><subject>Pandemics</subject><subject>Pandemics - prevention & control</subject><subject>Pediatrics</subject><subject>Pharmaceutical industry</subject><subject>Swine flu</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Vaccines, Attenuated - standards</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vaccines, Inactivated - standards</subject><subject>Viruses</subject><subject>Womens health</subject><subject>World Health Organization</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFks1u1DAUhS0EokPhEUCWWLCZDP53sgGhirZIlSpREOwsx7lpPWScwU4GdVa8A4_Am_EkOJ0pSN10Zfnq3M_33GOEnlOyoISq18vFxjrnAywYyTWiF4SLB2hGS80LJmn5EM0IU6IQlHw9QE9SWhJCJKfVY3TAiJKVZGSGfn-EdR8H3Ld4uAKshiu8Ahh8uMR9uCnBxnajHXy-ZtHahgZW3mEf2m6EsLV4P0fKJew6H7yzHR6it13CX_rYNfgUbJfB5_HSBr-9Yc3xCYSMnuOLH37YQuwyeI6p_vPzFy3xMdRxtPEaT-aeokdthsGz_XmIPh-__3R0Wpydn3w4endWOKHIUHDS1EqWwrHaUqiEU4JxChos5wpcw5mmklDBaMlERbkugbbOtpLJVpei5ofo1Y67jv33EdJgVj456PJo0I_JlFXuIoqX9yq1lFRJxnRWvryjXPZjDNmGoaLSjCkteVbJncrFPqUIrVlHv8r-DSVmitsszX7NZtqIIdrkuHPfiz19rFfQ_Ou6zTcL3u4EkPe28RBNch6Cg8ZHcINpen_vE2_uEG4z_gbXkP67MYkZYi6mPzd9OUoyhFWa_wXOzNKv</recordid><startdate>20101004</startdate><enddate>20101004</enddate><creator>Girard, Marc P</creator><creator>Katz, Jacqueline</creator><creator>Pervikov, Yuri</creator><creator>Palkonyay, Laszlo</creator><creator>Kieny, Marie-Paule</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20101004</creationdate><title>Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010</title><author>Girard, Marc P ; Katz, Jacqueline ; Pervikov, Yuri ; Palkonyay, Laszlo ; Kieny, Marie-Paule</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-30db6584c2ba1e94c64231e7ea336ecd327150142182491378e1fcaf525f784b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Cell culture</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical trials</topic><topic>Congresses as Topic</topic><topic>Eggs</topic><topic>H1N1 influenza</topic><topic>Humans</topic><topic>Infant</topic><topic>Influenza A Virus, H1N1 Subtype</topic><topic>Influenza A Virus, H5N1 Subtype</topic><topic>Influenza vaccines</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza Vaccines - standards</topic><topic>Influenza, Human - prevention & control</topic><topic>Licenses</topic><topic>Manufacturers</topic><topic>Meetings</topic><topic>Older people</topic><topic>Pandemic influenza</topic><topic>Pandemics</topic><topic>Pandemics - prevention & control</topic><topic>Pediatrics</topic><topic>Pharmaceutical industry</topic><topic>Swine flu</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Vaccines, Attenuated - standards</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vaccines, Inactivated - standards</topic><topic>Viruses</topic><topic>Womens health</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Girard, Marc P</creatorcontrib><creatorcontrib>Katz, Jacqueline</creatorcontrib><creatorcontrib>Pervikov, Yuri</creatorcontrib><creatorcontrib>Palkonyay, Laszlo</creatorcontrib><creatorcontrib>Kieny, Marie-Paule</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Girard, Marc P</au><au>Katz, Jacqueline</au><au>Pervikov, Yuri</au><au>Palkonyay, Laszlo</au><au>Kieny, Marie-Paule</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2010-10-04</date><risdate>2010</risdate><volume>28</volume><issue>42</issue><spage>6811</spage><epage>6820</epage><pages>6811-6820</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract On February 17–18, 2010, the World Health Organization (WHO) convened the 6th meeting on the “Evaluation of pandemic influenza vaccines in clinical trials” to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were reviewed, including classical egg-derived and cell culture-derived inactivated vaccines, such as split virus or whole-virion vaccines, and live-attenuated vaccines (LAIV), as well as vaccines developed using new technologies. The amount of antigen needed, the effect of adjuvants and the number of doses required to induce adequate antibody responses in various populations, together with the issue of safety of the vaccines, were major topics of the meeting. The effectiveness of H1N1 vaccines and the need for standardization of vaccine potency tests were also discussed. Independent of the vaccine type and the presence or absence of an adjuvant, all A (H1N1) 2009 vaccines were well tolerated, eliciting only mild to moderate local or systemic reactions. For most vaccines tested, a single dose was sufficient to elicit a potentially protective antibody response in the majority of vaccinees >10 years of age. However, a second dose of vaccine was needed to boost immune responses in infants and toddlers 6 months to 3 years of age and, with some vaccines, in children aged 3–9 years.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>20659520</pmid><doi>10.1016/j.vaccine.2010.07.034</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2010-10, Vol.28 (42), p.6811-6820 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_899130638 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Age Allergy and Immunology Antibodies, Viral - blood Cell culture Child Child, Preschool Clinical trials Congresses as Topic Eggs H1N1 influenza Humans Infant Influenza A Virus, H1N1 Subtype Influenza A Virus, H5N1 Subtype Influenza vaccines Influenza Vaccines - immunology Influenza Vaccines - standards Influenza, Human - prevention & control Licenses Manufacturers Meetings Older people Pandemic influenza Pandemics Pandemics - prevention & control Pediatrics Pharmaceutical industry Swine flu Vaccines Vaccines, Attenuated - immunology Vaccines, Attenuated - standards Vaccines, Inactivated - immunology Vaccines, Inactivated - standards Viruses Womens health World Health Organization |
| title | Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A46%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Report%20of%20the%206th%20meeting%20on%20the%20evaluation%20of%20pandemic%20influenza%20vaccines%20in%20clinical%20trials%20World%20Health%20Organization,%20Geneva,%20Switzerland,%2017%E2%80%9318%20February%202010&rft.jtitle=Vaccine&rft.au=Girard,%20Marc%20P&rft.date=2010-10-04&rft.volume=28&rft.issue=42&rft.spage=6811&rft.epage=6820&rft.pages=6811-6820&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2010.07.034&rft_dat=%3Cproquest_cross%3E3216318641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1497226753&rft_id=info:pmid/20659520&rft_els_id=S0264410X10010297&rfr_iscdi=true |